sprite-preloader
Anzeige
Mehr »
Montag, 11.12.2017 Börsentäglich über 12.000 News von 573 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
SaGilead makes bolt-on CAR-T buy after Kite deal
FrErytech rocked by phase 2b failure in AML
FrChutes & Ladders-AstraZeneca research exec jumps to startup Goldfinch
FrAmid harassment reports, Orbimed's Sam Isaly suddenly departs
FrJuno strikes 3 deals to advance multiple myeloma combo treatment
FrSage wows with phase 2 depression data, sending stock to new highs
FrNew data positive for Spark/Pfizer's hemophilia gene therapy
FrFDA opens door to multiarm, multicompany clinical trials
FrMetabolic biotech Metacrine gains $22M for NASH tests
DoActivating the hedgehog pathway protects mice from obesity
DoQuebec's Amorchem sets up $44M+ life sciences VC
DoAmgen, Carmot ink backloaded $240M Parkinson's pact
DoBiotech veteran Gilman heads CAR-T startup Obsidian
DoU.K.'s Brexit skeptic defying biopharma deal splash fizzles
MiMadrigal's NASH drug hits liver fat in midstage test
MiGalectin plunges on NASH cirrhosis midstage miss
MiRevance's rival to Allergan's Botox aces phase 3
MiIronwood's diabetes drug posts positive phase 2 data
MiERT buys iCardiac for clinical cardiac safety services boost
MiGoldfinch poaches AstraZeneca exec Tony Johnson for CEO
DiCellectis lures ex-Servier cancer R&D chief back to industry
DiBioclinica names new CEO, launches clinical adjudication
DiUltragenyx up on XLH drug's phase 3 success
DiOrbiMed, Peter Thiel back NASH mAb biotech
DiLoxo, Bayer maintain 90%-plus response rate in cancer trial